{"id":1112,"date":"2025-08-30T06:00:20","date_gmt":"2025-08-30T06:00:20","guid":{"rendered":"https:\/\/perfusfind.com\/ic\/?p=1112"},"modified":"2026-03-15T09:49:03","modified_gmt":"2026-03-15T09:49:03","slug":"neurally-adjusted-ventilatory-assist-in-critical-care-patients-with-and-without-obesity-a-prospective-randomized-crossover-study","status":"publish","type":"post","link":"https:\/\/perfusfind.com\/ic\/index.php\/2025\/08\/30\/neurally-adjusted-ventilatory-assist-in-critical-care-patients-with-and-without-obesity-a-prospective-randomized-crossover-study\/","title":{"rendered":"Neurally adjusted ventilatory assist in critical care patients with and without obesity: a prospective randomized crossover study"},"content":{"rendered":"

\ud83e\udec1 NAVA vs PSV in Obese ICU Patients: First Evidence of Safety and Benefit<\/h3>\n

 <\/p>\n

Abstract:<\/strong> This randomized crossover study is the first to test Neurally Adjusted Ventilatory Assist (NAVA) in critically ill obese patients<\/strong>. Twenty-one ventilated patients (10 obese, 11 non-obese) underwent 30 minutes of NAVA and PSV each. Researchers assessed safety, patient-ventilator synchrony, oxygenation, and variability.<\/p>\n

\n
\n
<\/div>\n<\/div>\n

Key Insights<\/h3>\n
    \n
  1. \n

    Feasibility:<\/strong> NAVA was feasible in all obese patients<\/strong>\u2014signal acquisition and ventilation were successful.<\/p>\n<\/li>\n

  2. \n

    Triggering:<\/strong> In obese patients, NAVA significantly reduced trigger delay<\/strong> (0 vs 106 ms) and inspiratory time in excess<\/strong> (96 vs 145 ms) compared to PSV.<\/p>\n<\/li>\n

  3. \n

    Dyssynchrony:<\/strong> Ineffective efforts were markedly lower with NAVA (0 vs 0.33\/min), although overall dyssynchrony index remained similar due to technical double triggering.<\/p>\n<\/li>\n

  4. \n

    Oxygenation:<\/strong> PaO\u2082\/FiO\u2082 ratio improved with NAVA (238 vs 207 mmHg).<\/p>\n<\/li>\n

  5. \n

    Ventilatory pattern:<\/strong> Tidal volumes were slightly lower with NAVA (6.7 vs 7.2 mL\/kg PBW), but variability in airway pressure and ventilation was greater<\/strong>, reflecting more physiologic breathing.<\/p>\n<\/li>\n

  6. \n

    Obesity effect:<\/strong> Outcomes with NAVA were similar in obese and non-obese patients<\/strong>; obesity did not impair safety or efficacy.<\/p>\n<\/li>\n

  7. \n

    Safety:<\/strong> No adverse events were observed in either group.<\/p>\n<\/li>\n<\/ol>\n

    \n
    \n
    <\/div>\n<\/div>\n

    Why This Matters<\/h3>\n

    Obesity complicates mechanical ventilation due to impaired lung mechanics and higher risk of dyssynchrony. This study shows NAVA is both feasible and advantageous in obese patients<\/strong>, enhancing synchrony and oxygenation while maintaining physiologic variability.<\/p>\n

    \n
    \n
    <\/div>\n<\/div>\n

    Conclusion<\/h3>\n

    NAVA is safe, feasible, and beneficial<\/strong> for critically ill obese patients compared with PSV. Larger studies are needed to determine if these physiological gains translate into shorter weaning times, fewer complications, and improved survival<\/strong>.<\/p>\n

    \n
    \n
    <\/div>\n<\/div>\n

    Take-Home for Clinicians<\/h3>\n